COO Cooper Companies Inc.

CooperCompanies to Present at Oppenheimer’s 33rd Annual Healthcare Conference

CooperCompanies to Present at Oppenheimer’s 33rd Annual Healthcare Conference

SAN RAMON, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- CooperCompanies (NYSE: COO), will participate in Oppenheimer’s 33rd Annual Healthcare Conference on Tuesday, March 14, 2022. Brian Andrews, Executive Vice President, Chief Financial Officer & Treasurer, will represent the Company in a virtual session scheduled to begin at 2:40 PM ET.

The webcast will be available to investors and other interested parties by accessing the CooperCompanies’ website at . A replay of the event will be available on the same webpage following its conclusion.

About CooperCompanies

CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE: COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, CA, Cooper has a workforce of more than 14,000 with products sold in over 100 countries. For more information, please visit .

Contact:

Kim Duncan

Vice President, Investor Relations and Risk Management

925-460-3663



EN
15/02/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cooper Companies Inc.

 PRESS RELEASE

CooperCompanies Announces Second Quarter 2025 Results

CooperCompanies Announces Second Quarter 2025 Results SAN RAMON, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal second quarter ended April 30, 2025. Revenue increased 6% year-over-year to $1,002.3 million. CooperVision (CVI) revenue up 5% to $669.6 million, and CooperSurgical (CSI) revenue up 8% to $332.7 million.GAAP diluted earnings per share (EPS) of $0.44, consistent with last year's second quarter.Non-GAAP diluted EPS of $0.96, up $0.11 or 14% from last year's second qu...

 PRESS RELEASE

CooperCompanies’ 2024 Sustainability Report Showcases Efforts that Ben...

CooperCompanies’ 2024 Sustainability Report Showcases Efforts that Benefit People and the Planet SAN RAMON, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (“Cooper”) (Nasdaq: COO), a leading medical device company, published its . The report showcases the company’s initiatives to foster positive change for both people and the planet and provides expanded and updated sustainability performance data. In 2024, CooperCompanies maintained strong partnerships to reduce its plastic footprint, earned a number of sustainability certifications, and supported employee growth with signifi...

 PRESS RELEASE

CooperCompanies to Participate in the William Blair Growth Stock Confe...

CooperCompanies to Participate in the William Blair Growth Stock Conference SAN RAMON, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today it will participate in the William Blair Growth Stock Conference on Thursday, June 5, 2025. Brian Andrews, Executive Vice President, Chief Financial Officer & Treasurer, will represent the Company in a session scheduled at 11:20 AM CT. The webcast will be available to investors and other interested parties by accessing the CooperCompanies’ website at . About CooperCompaniesC...

 PRESS RELEASE

CooperCompanies Appoints Barbara Carbone to Board of Directors

CooperCompanies Appoints Barbara Carbone to Board of Directors SAN RAMON, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today that its Board of Directors has appointed Barbara Carbone as an independent director, effective May 1, 2025. Ms. Carbone has also been appointed to serve on the Audit Committee when she joins the Board. Ms. Carbone brings nearly four decades of experience across a wide variety of industries. She spent most of her career at KPMG LLP, from 1981-2019, where she served more than twenty-four...

 PRESS RELEASE

CooperCompanies Announces Release Date for Second Quarter 2025

CooperCompanies Announces Release Date for Second Quarter 2025  SAN RAMON, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today it will report second quarter 2025 financial results on Thursday, May 29, 2025, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 1515103. A simultaneous audio webcast and subsequent replay can be accessed at . About Coo...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch